Table 1 Foundational characteristics of ENKTL subjects in 4 cohorts

From: Development and validation of a predictive model for extranodal natural killer/T-cell lymphoma

Variables

Training cohort

N = 450

Evaluation cohort

N = 194

External validation cohort 1

N = 187

External validation cohort 2

N = 146

Median follow-up (months)

46.5 (40.9–52.0)

50.3 (41.8–58.9)

56.9 (42.2–74.9)

34.0 (17.8–61.9)

Age (years)

44.4 ± 15.2

42.4 ± 13.4

43.7 ± 13.5

48.3 ± 15.9

Male sex, n (%)

306 (68.0)

140 (72.2)

124 (66.3)

99 (67.8)

ECOG PS

 0–1

435 (96.7)

192 (99.0)

164 (87.7)

144 (98.6)

 ≥2

15 (3.3)

2 (1.0)

23 (12.3)

2 (1.4)

B symptoms

 No

246 (54.7)

97 (55.0)

69 (36.9)

100 (68.5)

 Yes

204 (45.3)

97 (55.0)

118 (63.1)

46 (31.5)

Ann Arbor staging

 I–II

332 (73.8)

143 (73.7)

137 (73.3)

109 (74.7)

 III–IV

118 (26.2)

51 (26.3)

50 (26.7)

37 (25.3)

 EBV-DNA copy number (copies/ml)

550 (0–8125)

360 (0–1955)

401 (0–2907)

126 (0–4745)

 LDH (U/L)

209.6 (172.6–285.1)

203.7 (163.0–260.0)

207 (173.0–264.0)

192.0 (166.8–249.5)

 Ki67 proliferative index

70 (50–80)

70 (50–70)

60 (40–70)

60 (40–71)

PTI

 Absent

156 (34.7)

75 (38.7)

67 (35.8)

61 (41.8)

 Present

294 (65.3)

119 (61.3)

120 (64.2)

85 (58.2)

Primary site

 UADT

382 (84.9)

161 (83.0)

156 (83.4)

138 (94.5)

 Extra-UADT

68 (15.1)

33 (17.0)

31 (16.6)

8 (5.5)

Bone marrow involvement

 Absent

414 (92.0)

189 (97.4)

175 (93.6)

141 (96.6)

 Present

36 (8.0)

5 (2.6)

12 (6.4)

5 (3.4)

Distant LN

 Absent

366 (81.3)

155 (79.9)

149 (79.7)

124 (84.9)

 Present

84 (18.7)

39 (20.1)

38 (20.3)

22 (15.1)

Extranodal sites

 0–1

342 (76.0)

152 (78.4)

144 (77.0)

99 (67.8)

 ≥2

108 (24.0)

42 (21.6)

43 (23.0)

47 (32.2)

Regional LN

 Absent

205 (45.6)

97 (50.0)

75 (40.1)

62 (42.5)

 Present

245 (54.4)

97 (50.0)

112 (59.9)

84 (57.5)

Primary treatment

 Chemotherapy

120 (26.7)

56 (28.9)

37 (19.8)

100 (68.5)

 Radiotherapy

4 (0.9)

1 (0.5)

1 (0.5)

2 (1.4)

 CMTa

188 (41.8)

88 (45.4)

128 (68.4)

43 (29.5)

 Anti-PD-1b

138 (30.7)

49 (25.3)

21 (11.2)

1 (0.6)

Chemotherapy regimen

 GEMOX/GDP/GDM + L-asparaginase

278 (61.8)

121 (62.4)

49 (26.3)

112 (76.7)

 GLIDE/DDGP

0

0

113 (60.4)

9 (6.2)

 AspaMetDex

24 (5.3)

10 (5.2)

1 (0.5)

0

 SMILE

17 (3.8)

13 (6.7)

9 (4.8)

3 (2.1)

 ICE/IMEP

22 (4.9)

14 (7.2)

0

3 (2.1)

 DeVIC/VIPD

4 (0.9)

3 (1.5)

5 (2.7)

0

 L-asparaginasec

69 (15.3)

23 (11.9)

9 (4.8)

19 (13.0)

 Non-anthracycline-based regimensc

32 (7.1)

9 (4.6)

0

0

  1. Continuous variables are expressed as the mean ± standard deviation or median (interquartile range).
  2. ECOG Eastern Cooperative Oncology Group, PS performance status, LDH lactic dehydrogenase, EBV Epstein-Barr virus, LN lymph node, UADT upper aerodigestive tract, PTI primary tumor invasion, GEMOX gemcitabine, and oxaliplatin, GDP gemcitabine, dexamethasone, and cisplatin, GDM gemcitabine, dexamethasone, and methotrexate, GLIDE gemcitabine, L-asparaginase, ifosfamide, dexamethasone, and etoposide, DDGP cisplatin, dexamethasone, gemcitabine, and L-asparaginase, AspaMetDex L-asparaginase, methotrexate, and dexamethasone, SMILE corticosteroids, methotrexate, ifosfamide, L-asparaginase, and etoposide, ICE ifosfamide, carboplatin, and etoposide, IMEP ifosfamide, methotrexate, etoposide, and prednisolone, DeVIC dexamethasone, etoposide, ifosfamide, and carboplatin, VIPD etoposide, ifosfamide, cisplatin, and dexamethasone.
  3. aCombinational modality treatment (CMT) denotes a combination of radiotherapy and chemotherapy.
  4. bAnti-PD-1 denotes combinational anti-PD-1 therapy.
  5. cExcludes previously listed regimens.
Back to article page